Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

BACKGROUND: Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Malagola, Michele, Iurlo, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D’Adda, Mariella, Lunghi, Monia, Crugnola, Monica, Ferrari, Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli, Roberto M., Sancetta, Rosaria, Coppi, Maria Rosaria, Corsetti, Maria Teresa, Rege Cambrin, Giovanna, Romano, Atelda, Tiribelli, Mario, Russo Rossi, Antonella, Russo, Sabina, Aprile, Lara, Bocchia, Monica, Gandolfi, Lisa, Farina, Mirko, Bernardi, Simona, Polverelli, Nicola, Roccaro, Aldo M., De Vivo, Antonio, Baccarani, Michele, Russo, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940223/
https://www.ncbi.nlm.nih.gov/pubmed/33594821
http://dx.doi.org/10.1002/cam4.3778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940223/
https://www.ncbi.nlm.nih.gov/pubmed/33594821
http://dx.doi.org/10.1002/cam4.3778

Ejemplares similares